TGTX
TG Therapeutics, Inc. NASDAQ Listed May 3, 2010$43.02
Mkt Cap $6.9B
52w Low $25.28
94.8% of range
52w High $44.00
50d MA $32.58
200d MA $31.86
P/E (TTM)
10.9x
EV/EBITDA
33.4x
P/B
7.5x
Debt/Equity
0.4x
ROE
69.0%
P/FCF
-172.2x
RSI (14)
—
ATR (14)
—
Beta
1.75
50d MA
$32.58
200d MA
$31.86
Avg Volume
1.9M
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
2 Gansevoort Street · Morrisville, NY 10014 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | BMO | 0.35 | 0.14 | -60.0% | 30.90 | -1.1% | -2.6% | -2.3% | -1.8% | +1.1% | -0.5% | — |
| Nov 3, 2025 | BMO | 0.24 | 2.43 | +912.5% | 33.69 | -1.8% | +0.4% | +0.7% | -2.3% | -3.1% | -6.0% | — |
| Aug 4, 2025 | BMO | 0.32 | 0.17 | -46.9% | 28.72 | +1.3% | -1.1% | -2.5% | +0.7% | -4.2% | -1.2% | — |
| May 5, 2025 | BMO | 0.18 | 0.03 | -83.3% | 37.68 | -1.1% | -7.5% | -0.0% | -2.8% | -0.6% | +4.0% | — |
| Mar 3, 2025 | BMO | 0.08 | 0.15 | +87.5% | 34.42 | +0.0% | +3.5% | -1.4% | +0.2% | +9.2% | +2.1% | — |
| Nov 4, 2024 | BMO | 0.03 | 0.02 | -33.3% | 24.36 | +0.5% | +6.2% | +5.1% | +2.7% | +3.3% | +6.7% | — |
| Aug 6, 2024 | BMO | -0.05 | 0.04 | +180.0% | 20.58 | +4.0% | -2.9% | +0.3% | -0.6% | +3.7% | +2.8% | — |
| May 1, 2024 | BMO | -0.04 | -0.07 | -96.1% | 15.88 | +2.0% | +3.4% | -1.4% | +2.0% | +4.1% | -0.3% | — |
| Feb 28, 2024 | BMO | -0.12 | -0.09 | +25.0% | 17.63 | +1.2% | -2.3% | +4.3% | -0.5% | +1.2% | +0.8% | — |
| Nov 1, 2023 | BMO | 0.12 | 0.73 | +508.3% | 10.12 | +0.0% | +2.9% | +6.2% | -7.3% | +5.7% | -0.4% | — |
| Aug 1, 2023 | BMO | -0.26 | -0.34 | -30.8% | 10.49 | +1.7% | +0.6% | +6.2% | -4.4% | -5.7% | -4.5% | — |
| May 1, 2023 | BMO | -0.36 | -0.28 | +22.2% | 30.64 | +0.6% | +1.7% | +11.9% | +0.4% | -2.0% | -3.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 2 | JP Morgan | Maintains | Overweight → Overweight | — | $29.43 | $29.20 | -0.8% | -0.8% | +1.9% | -2.1% | -4.7% | +4.0% |
| Jan 15 | Goldman Sachs | Maintains | Neutral → Neutral | — | $29.54 | $29.54 | +0.0% | +4.0% | -0.5% | +1.2% | +2.0% | +0.2% |
| Nov 3 | JP Morgan | Maintains | Overweight → Overweight | — | $34.78 | $36.30 | +4.4% | -3.1% | +0.4% | +0.7% | -2.3% | -3.1% |
| Sep 17 | B. Riley Securities | Maintains | Buy → Buy | — | $31.99 | $32.16 | +0.5% | +0.2% | +1.8% | -0.7% | +8.0% | +1.7% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.42 | $34.42 | +0.0% | +3.5% | -1.4% | +0.2% | +9.2% | +2.1% |
| Jan 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.74 | $30.67 | +3.1% | +1.5% | -3.4% | +1.4% | +1.0% | -2.4% |
| Nov 25 | JP Morgan | Maintains | Overweight → Overweight | — | $35.07 | $35.89 | +2.3% | -1.3% | -1.0% | +2.2% | -0.6% | +0.8% |
| Nov 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.36 | $24.49 | +0.5% | +6.2% | +5.1% | +2.7% | +3.3% | +6.7% |
| Nov 5 | Goldman Sachs | Maintains | Neutral → Neutral | — | $24.36 | $24.49 | +0.5% | +6.2% | +5.1% | +2.7% | +3.3% | +6.7% |
| Sep 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.08 | $26.25 | +4.7% | +0.7% | +0.1% | -2.5% | -5.7% | +0.3% |
| Aug 7 | Goldman Sachs | Maintains | Neutral → Neutral | — | $20.58 | $21.40 | +4.0% | -2.9% | +0.3% | -0.6% | +3.7% | +2.8% |
| Aug 7 | B. Riley Securities | Maintains | Buy → Buy | — | $20.58 | $21.40 | +4.0% | -2.9% | +0.3% | -0.6% | +3.7% | +2.8% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.21 | $19.07 | +10.8% | +19.6% | -2.9% | +0.3% | -0.6% | +3.7% |
| May 2 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $15.88 | $16.20 | +2.0% | +3.4% | -1.4% | +2.0% | +4.1% | -0.3% |
| May 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.88 | $16.20 | +2.0% | +3.4% | -1.4% | +2.0% | +4.1% | -0.3% |
| Apr 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.82 | $13.99 | +1.2% | +1.2% | -1.5% | +2.3% | +1.1% | -1.9% |
| Apr 18 | JP Morgan | Maintains | Overweight → Overweight | — | $13.82 | $13.99 | +1.2% | +1.2% | -1.5% | +2.3% | +1.1% | -1.9% |
| Apr 18 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $13.82 | $13.99 | +1.2% | +1.2% | -1.5% | +2.3% | +1.1% | -1.9% |
| Mar 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.22 | $17.54 | +1.9% | +4.3% | -0.5% | +1.2% | +0.8% | -1.3% |
| Feb 29 | Goldman Sachs | Maintains | Neutral → Neutral | — | $17.63 | $17.85 | +1.2% | -2.3% | +4.3% | -0.5% | +1.2% | +0.8% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.91 | $16.18 | +16.3% | +26.7% | -2.3% | +4.3% | -0.5% | +1.2% |
| Feb 5 | B. Riley Securities | Maintains | Buy → Buy | — | $16.46 | $16.48 | +0.1% | -7.0% | +0.3% | -6.4% | +1.9% | +0.7% |
| Jan 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.77 | $17.68 | -0.5% | -3.1% | -8.4% | -3.9% | +0.9% | -1.0% |
| Nov 1 | JP Morgan | Maintains | Overweight → Overweight | — | $7.73 | $10.19 | +31.8% | +30.9% | +2.9% | +6.2% | -7.3% | +5.7% |
| Nov 1 | Jefferies | Maintains | Buy → Buy | — | $7.73 | $10.19 | +31.8% | +30.9% | +2.9% | +6.2% | -7.3% | +5.7% |
| Oct 20 | B. Riley Securities | Maintains | Buy → Buy | — | $6.68 | $6.68 | +0.0% | +1.0% | -0.9% | +10.8% | -5.3% | +2.6% |
| Sep 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.14 | $10.00 | -1.4% | -6.2% | +0.8% | -3.0% | -0.5% | -1.2% |
| Aug 7 | JP Morgan | Maintains | Overweight → Overweight | — | $10.71 | $10.65 | -0.6% | -5.7% | -4.5% | +0.3% | +0.2% | +4.4% |
| Aug 3 | Goldman Sachs | Maintains | Neutral → Neutral | — | $10.55 | $10.59 | +0.4% | +6.2% | -4.4% | -5.7% | -4.5% | +0.3% |
| Aug 2 | Goldman Sachs | Upgrade | Sell → Neutral | — | $10.49 | $10.67 | +1.7% | +0.6% | +6.2% | -4.4% | -5.7% | -4.5% |
| Aug 2 | B. Riley Securities | Maintains | Buy → Buy | — | $10.49 | $10.67 | +1.7% | +0.6% | +6.2% | -4.4% | -5.7% | -4.5% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.69 | $11.88 | -42.6% | -49.3% | +0.6% | +6.2% | -4.4% | -5.7% |
| Aug 1 | B. Riley Securities | Maintains | Buy → Buy | — | $20.69 | $11.88 | -42.6% | -49.3% | +0.6% | +6.2% | -4.4% | -5.7% |
| Jul 25 | Goldman Sachs | Maintains | Sell → Sell | — | $20.28 | $20.24 | -0.2% | -0.7% | +0.4% | -2.0% | -0.6% | +5.0% |
| Jul 24 | Goldman Sachs | Maintains | Sell → Sell | — | $20.62 | $20.65 | +0.1% | -1.6% | -0.7% | +0.4% | -2.0% | -0.6% |
| Jul 13 | B. Riley Securities | Maintains | Buy → Buy | — | $25.46 | $23.00 | -9.7% | -14.6% | +1.6% | -2.8% | -0.5% | -0.6% |
| May 2 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $30.64 | $30.82 | +0.6% | +1.7% | +11.9% | +0.4% | -2.0% | -3.5% |
| Feb 7 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $18.48 | $18.73 | +1.4% | -0.3% | -2.9% | -2.1% | +2.2% | +2.7% |
| Jan 24 | Evercore ISI | Maintains | Outperform → Outperform | — | $12.69 | $13.18 | +3.9% | +14.0% | -1.7% | -0.6% | +3.4% | -0.9% |
| Dec 30 | Goldman Sachs | Maintains | Sell → Sell | — | $10.40 | $10.91 | +4.9% | +13.8% | -2.2% | -7.3% | -4.6% | +5.6% |
| Dec 30 | Evercore ISI | Maintains | Outperform → Outperform | — | $10.40 | $10.91 | +4.9% | +13.8% | -2.2% | -7.3% | -4.6% | +5.6% |
| Dec 30 | B. Riley Securities | Maintains | Buy → Buy | — | $10.40 | $10.91 | +4.9% | +13.8% | -2.2% | -7.3% | -4.6% | +5.6% |
| Dec 29 | BofA Securities | Maintains | Underperform → Underperform | — | $8.46 | $9.18 | +8.5% | +22.9% | +13.8% | -2.2% | -7.3% | -4.6% |
| Dec 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.46 | $9.18 | +8.5% | +22.9% | +13.8% | -2.2% | -7.3% | -4.6% |
| Jun 13 | B. Riley Securities | Maintains | Buy → Buy | — | $4.59 | $4.40 | -4.1% | -10.0% | -6.8% | +0.5% | -3.4% | +8.0% |
| Apr 19 | B. Riley Securities | Maintains | Buy → Buy | — | $6.92 | $6.76 | -2.3% | +4.9% | +5.9% | -3.5% | -3.9% | +4.8% |
| Apr 19 | Goldman Sachs | Maintains | Sell → Sell | — | $6.92 | $6.76 | -2.3% | +4.9% | +5.9% | -3.5% | -3.9% | +4.8% |
| Apr 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.85 | $6.03 | -31.9% | -21.8% | +4.9% | +5.9% | -3.5% | -3.9% |
| Jan 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.27 | $8.46 | +2.3% | +17.7% | +18.9% | +1.7% | -6.7% | -7.7% |
| Jan 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.57 | $13.50 | -0.5% | +6.6% | +2.1% | -5.8% | -40.5% | +17.7% |
No insider trades available.
8-K · 2.02
!! High
TG Therapeutics, Inc. -- 8-K 2.02: Earnings Results
TG Therapeutics reported Q1 2026 financial results, providing investors with updated operational performance metrics and financial conditions for the first quarter.
May 6
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
Without specific details about the material agreement's terms, financial impact, or strategic importance, investors cannot assess whether this development positively or negatively affects shareholder value.
Mar 20
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The departure of TGTX's Chief Strategy Officer and Head of Commercial signals potential disruption to commercial execution and strategic planning during a critical period for the biotech company.
Mar 17
8-K
TG Therapeutics, Inc. -- 8-K Filing
TG Therapeutics raised 2026 revenue guidance to $875-900 million on strong 2025 BRIUMVI sales of $594.1 million, signaling robust commercial momentum for its key drug.
Feb 26
Data updated apr 27, 2026 4:39am
· Source: massive.com